Taro markets a broad range of prescription and over-the-counter products in the United States. We are a leading manufacturer and supplier of topical dermatological products and also have a growing line of solid dosage form products used mainly in cardiology and neurology.
We’re proud that millions of Americans rely on our generic pharmaceuticals and over-the-counter private-label products every year. Whether you're a physician, pharmacist or patient, please consider this website your personal resource for learning more about Taro.
June 14, 2010
Taro Provides Preliminary First Quarter 2010 Financial Results
More 
June 03, 2010
Taro Receives FDA Approval for Granisetron Hydrochloride Tablets
More
April 30, 2010
Taro Provides Preliminary 2009 Full Year Results
More
April 06, 2010
Taro Receives Patent for T2007, the Company's Second Proprietary Non-Sedating Barbiturate Drug
More
March 25, 2010
Taro Files Audited Financials for the Year Ended December 31, 2006 and Restated Financials for 2005 and 2004
More
March 8, 2010
Taro Receives FDA Approval for Fluorouracil Topical Cream USP, 5%
More
February 18, 2010
Taro Announces Planned Discontinuation of Manufacturing Operations at Its Irish Facility
More
February 4, 2010
Israel Supreme Court Prohibits Sun From Exercising Warrant While Temporary Junction In Affect
More
February 2, 2010
Taro Receives FDA Approval For Levetiracetam Tablets
More